Literature DB >> 22349862

Endocrine function in 97 patients with myotonic dystrophy type 1.

M C Ørngreen1, P Arlien-Søborg, M Duno, J M Hertz, J Vissing.   

Abstract

The aim of this study was to investigate the endocrine function and its association to number of CTG repeats in patients with myotonic dystrophy type 1 (DM1). Concentration of various hormones and metabolites in venous blood was used to assess the endocrine function in 97 patients with DM1. Correlation with CTG(n) expansion size was investigated with the Pearson correlation test. Eighteen percent of the DM1 patients had hyperparathyroidism with increased PTH compared with 0.5% in the background population. Of these, 16% had normocalcemia and 2% had hypercalcemia. An additional 3% had hypercalcemia without elevation of PTH; 7% had abnormal TSH values (2% subnormal and 5% elevated TSH levels); 5% of the patients had type 2 diabetes mellitus; 17% of the male DM1 patients had increased LH and low levels of plasma testosterone indicating absolute androgen insufficiency. Another 21% had increased LH, but normal testosterone levels, indicating relative insufficiency. Numbers of CTG repeats correlated directly with plasma PTH, phosphate, LH, and tended to correlate with plasma testosterone for males. This is the largest study of endocrine dysfunction in a cohort of Caucasian patients with DM1. We found that patients with DM1 have an increased risk of abnormal endocrine function, particularly calcium metabolism disorders. However, the endocrine dysfunction appears not to be of clinical significance in all of the cases. Finally, we found correlations between CTG(n) expansion size and plasma PTH, phosphate, and testosterone, and neck flexion strength.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349862     DOI: 10.1007/s00415-011-6277-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  Effect of testosterone on muscle mass and muscle protein synthesis.

Authors:  R C Griggs; W Kingston; R F Jozefowicz; B E Herr; G Forbes; D Halliday
Journal:  J Appl Physiol (1985)       Date:  1989-01

2.  Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy?

Authors:  N R Clarke; A D Kelion; J Nixon; D Hilton-Jones; J C Forfar
Journal:  Heart       Date:  2001-10       Impact factor: 5.994

3.  Myotonic dystrophy and hyperthyroidism.

Authors:  T Okuno; K Mori; K Furomi; T Takeoka; K Kondo
Journal:  Neurology       Date:  1981-01       Impact factor: 9.910

4.  Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.

Authors:  R S Savkur; A V Philips; T A Cooper
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

5.  Comparison of CTG repeat length expansion and clinical progression of myotonic dystrophy over a five year period.

Authors:  L Martorell; J M Martinez; N Carey; K Johnson; M Baiget
Journal:  J Med Genet       Date:  1995-08       Impact factor: 6.318

6.  Association of primary hyperparathyroidism with myotonic dystrophy in two patients.

Authors:  S Harada; T Matsumoto; K Ikeda; S Fukumoto; Y Ihara; E Ogata
Journal:  Arch Intern Med       Date:  1987-04

7.  Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1).

Authors:  Richard T Moxley; Eric L Logigian; William B Martens; Chris L Annis; Shree Pandya; Richard T Moxley; Cheryl A Barbieri; Nuran Dilek; Allen W Wiegner; Charles A Thornton
Journal:  Muscle Nerve       Date:  2007-09       Impact factor: 3.217

8.  Positive correlation of CTG expansion and pharyngoesophageal alterations in myotonic dystrophy patients.

Authors:  M Marcon; C Briani; M Ermani; E Menegazzo; V Iurilli; G P Feltrin; G Novelli; M Gennarelli; C Angelini
Journal:  Ital J Neurol Sci       Date:  1998-04

9.  Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy.

Authors:  I Mastrogiacomo; G Bonanni; E Menegazzo; C Santarossa; E Pagani; M Gennarelli; C Angelini
Journal:  Ital J Neurol Sci       Date:  1996-02

10.  MSH2 ATPase domain mutation affects CTG*CAG repeat instability in transgenic mice.

Authors:  Stéphanie Tomé; Ian Holt; Winfried Edelmann; Glenn E Morris; Arnold Munnich; Christopher E Pearson; Geneviève Gourdon
Journal:  PLoS Genet       Date:  2009-05-15       Impact factor: 5.917

View more
  13 in total

1.  Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors.

Authors:  Maria Laura Ester Bianchi; Emanuele Leoncini; Marcella Masciullo; Anna Modoni; Shahinaz M Gadalla; Roberto Massa; Emanuele Rastelli; Chiara Terracciano; Giovanni Antonini; Elisabetta Bucci; Antonio Petrucci; Sandro Costanzi; Massimo Santoro; Stefania Boccia; Gabriella Silvestri
Journal:  J Neurol       Date:  2016-01-06       Impact factor: 4.849

2.  Study of anti-Müllerian hormone levels in patients with Myotonic Dystrophy Type 1. Preliminary results.

Authors:  Manuela Ergoli; Massimo Venditti; Raffaele Dotolo; Esther Picillo; Sergio Minucci; Luisa Politano
Journal:  Acta Myol       Date:  2017-12-01

3.  Hormonal and metabolic gender differences in a cohort of myotonic dystrophy type 1 subjects: a retrospective, case-control study.

Authors:  M Spaziani; A Semeraro; E Bucci; F Rossi; M Garibaldi; M A Papassifachis; C Pozza; A Anzuini; A Lenzi; G Antonini; A F Radicioni
Journal:  J Endocrinol Invest       Date:  2019-11-30       Impact factor: 4.256

4.  Vitamin D deficiency in myotonic dystrophy type 1.

Authors:  Chiara Terracciano; Emanuele Rastelli; Maria Morello; Monica Celi; Elisabetta Bucci; Giovanni Antonini; Ottavia Porzio; Umberto Tarantino; Rossella Zenobi; Roberto Massa
Journal:  J Neurol       Date:  2013-06-11       Impact factor: 4.849

5.  Predicting daytime sleepiness and fatigue: a 9-year prospective study in myotonic dystrophy type 1.

Authors:  Luc Laberge; Benjamin Gallais; Julie Auclair; Yves Dauvilliers; Jean Mathieu; Cynthia Gagnon
Journal:  J Neurol       Date:  2019-10-31       Impact factor: 4.849

6.  Primary Hyperparathyroidism and Hyperthyroidism in a Patient with Myotonic Dystrophy: A Case Report and Review of the Literature.

Authors:  Yosra Cherif; Baha Zantour; Wafa Alaya; Olfa Berriche; Samia Younes; Mohamed Habib Sfar
Journal:  Case Rep Endocrinol       Date:  2015-06-15

7.  Myotonic Dystrophy Type 1 with Syringomyelia in a Young Patient.

Authors:  Xiao-Lin Yu; Ru-Zhen Jia; Pei-Yan Shan; Chuan-Zhu Yan; Ai-Fen Liu
Journal:  Chin Med J (Engl)       Date:  2016-02-20       Impact factor: 2.628

8.  Risk factors for osteoporosis, falls and fractures in hereditary myopathies and sporadic inclusion body myositis - A cross sectional survey.

Authors:  F Danckworth; N Karabul; A Posa; F Hanisch
Journal:  Mol Genet Metab Rep       Date:  2014-02-11

9.  Diabetes, metformin and cancer risk in myotonic dystrophy type I.

Authors:  Rotana Alsaggaf; Ruth M Pfeiffer; Youjin Wang; Diane Marie M St George; Min Zhan; Kathryn R Wagner; Sania Amr; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2019-12-19       Impact factor: 7.316

Review 10.  Muscle wasting in myotonic dystrophies: a model of premature aging.

Authors:  Alba Judith Mateos-Aierdi; Maria Goicoechea; Ana Aiastui; Roberto Fernández-Torrón; Mikel Garcia-Puga; Ander Matheu; Adolfo López de Munain
Journal:  Front Aging Neurosci       Date:  2015-07-09       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.